Remicade 2016 U.S. PROMOTIONAL AUDIT REPORT

Published July 2017 • 27 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Remicade through personal promotion in 2016 and how does this compare to its peer set in the Ankylosing Spondylitis, Crohn’s Disease, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does J&J’s depth of coverage vary within key specialties (e.g., Gastroenterology, Dermatology, Rheumatology, Internal Medicine, and Pediatric Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Remicade throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers for Remicade in 2016?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
• Over 37,700 paid interactions across 8,700 physicians made on behalf of Remicade were carefully examined to support our analysis. In addition, interaction data from 24 peer products (e.g. Actemra, Apriso, Cimzia, Cosentyx, Enbrel, Enstilar, Entyvio, Humira, Ilaris, Kineret, Lialda, Orencia, Otezla, Otrexup, Pentasa, Rasuvo, Rayos, Rituxan, Servino, Simponi, Stelara, Taltz, Uceris, and Xeljanz ) was leveraged to provide benchmarking and market insights.